Free Trial

AcelRx Pharmaceuticals (ACRX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
243,500 shs
Average Volume
137,683 shs
Market Capitalization
$14.58 million
P/E Ratio
Dividend Yield
Price Target

AcelRx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
∞ Upside
$4.63 Price Target
Short Interest
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($0.40) to ($0.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.36 out of 5 stars

Medical Sector

748th out of 914 stocks

Pharmaceutical Preparations Industry

351st out of 433 stocks

ACRX stock logo

About AcelRx Pharmaceuticals Stock (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

ACRX Stock News Headlines

This student turned $1,300 into $45,000 in just 4 Months!
With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.
This student turned $1,300 into $45,000 in just 4 Months!
With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.
AcelRx CEO buys 10,000 shares
Positive Report for Acelrx (ACRX) from H.C. Wainwright
See More Headlines
Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
$47.76 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.77 million
Book Value
$2.65 per share


Free Float
Market Cap
$14.58 million
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Vincent J. Angotti (Age 56)
    CEO & Director
    Comp: $906.54k
  • Dr. Pamela Pierce Palmer M.D. (Age 61)
    Ph.D., Co-Founder, Chief Medical Officer & Director
    Comp: $699.75k
  • Mr. Raffi Mark Asadorian (Age 55)
    Chief Financial Officer
    Comp: $637.5k
  • Mr. Anil N. Dasu (Age 61)
    Chief Engineering Officer
    Comp: $478.09k

ACRX Stock Analysis - Frequently Asked Questions

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.40). The specialty pharmaceutical company earned $1.86 million during the quarter, compared to analyst estimates of $1.20 million.

When did AcelRx Pharmaceuticals' stock split?

Shares of AcelRx Pharmaceuticals reverse split before market open on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX) and OPKO Health (OPK).

This page (NASDAQ:ACRX) was last updated on 7/17/2024 by Staff

From Our Partners